These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1898680)

  • 1. Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part I.
    Becker RC; Corrao JM; Harrington R; Ball SP; Gore JM
    Am Heart J; 1991 Jan; 121(1 Pt 1):220-44. PubMed ID: 1898680
    [No Abstract]   [Full Text] [Related]  

  • 2. Conservative management complications after thrombolytic therapy.
    Mohler ER; Stark KS; Kent KM
    Am Heart J; 1991 Feb; 121(2 Pt 1):591-3. PubMed ID: 1899317
    [No Abstract]   [Full Text] [Related]  

  • 3. The obsession with primary angioplasty.
    Melandri G
    Circulation; 2003 Dec; 108(23):e162. PubMed ID: 14662697
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction--a report from the multicenter thrombolysis trial.
    Kanemoto N; Goto Y; Hirosawa K; Kawai C; Kimata S; Yui Y; Yamamoto Y
    Jpn Circ J; 1990 Jan; 54(1):71-81. PubMed ID: 2110271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases].
    Izaguirre Avila R; Ruiz de Chávez Cervantes A; Villavicencio R; Gómez Trigos A; Mar Chavira R; Spíndola Mdel C; Casanova JM
    Arch Inst Cardiol Mex; 1993; 63(3):235-40. PubMed ID: 8347053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant tissue-type plasminogen activator in acute myocardial infarction: role of the critical care nurse.
    Kline EM
    Heart Lung; 1987 Nov; 16(6 Pt 2):779-86. PubMed ID: 2960639
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute myocardial infarction and thrombolytic therapy.
    Yasuda T; Gold HK
    Thromb Res Suppl; 1990; 10():73-9. PubMed ID: 2107600
    [No Abstract]   [Full Text] [Related]  

  • 8. [Thrombolytic therapy with tissue-type plasminogen activator].
    Toma M; Yamaguchi T
    Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):797-801. PubMed ID: 12436618
    [No Abstract]   [Full Text] [Related]  

  • 9. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
    Collen D
    Ann Intern Med; 1990 Apr; 112(7):529-38. PubMed ID: 2107781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of time required for reperfusion (thrombolysis or angioplasty, or both) and location of acute myocardial infarction on left ventricular functional reserve capacity several months later.
    Little T; Crenshaw M; Liberman HA; Battey LL; Warner R; Churchwell AL; Eisner RL; Morris DC; Patterson RE
    Am J Cardiol; 1991 Apr; 67(9):797-805. PubMed ID: 1901437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction.
    Ward SR; Sutton JM; Pieper KS; Schwaiger M; Califf RM; Topol EJ
    Am J Cardiol; 1997 Mar; 79(5):539-44. PubMed ID: 9068505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].
    Motomiya T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():441-5. PubMed ID: 12735012
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary percutaneous coronary intervention.
    Gurewich V
    N Engl J Med; 2008 Jan; 358(4):431-2; author reply 432-3. PubMed ID: 18219753
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.
    Sane DC; Stump DC; Topol EJ; Sigmon KN; Kereiakes DJ; George BS; Mantell SJ; Macy E; Collen D; Califf RM
    Thromb Haemost; 1991 Mar; 65(3):275-9. PubMed ID: 1904653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous SM-9527 (double-chain tissue plasminogen activator) on left ventricular function in the chronic stage of acute myocardial infarction.
    Hayashi H; Takatsu F; Sone T; Mizutani N; Hirayama H; Osugi J; Yamauchi K; Ogawa H; Watanabe T; Saito H
    Clin Cardiol; 1993 May; 16(5):409-14. PubMed ID: 8504575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Case report. Thrombolytic therapy 17 hours after acute myocardial infarct: assessing myocardial viability with 201 thallium imaging].
    Lund GK; Koschyk DH; Nienaber CA
    Herz; 1994 Feb; 19(1):65-8. PubMed ID: 8150415
    [No Abstract]   [Full Text] [Related]  

  • 17. Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.
    Möckel M; Bocksch W; Strohm S; Kühnle Y; Vollert J; Nibbe L; Dietz R
    Int J Cardiol; 2005 Aug; 103(2):193-200. PubMed ID: 16080980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction.
    Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators
    N Engl J Med; 1997 Jun; 336(23):1621-8. PubMed ID: 9173270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolysis in acute myocardial infarction.
    Holmberg SR
    Br J Hosp Med; 1992 Apr 15-May 5; 47(8):572-6, 578-80. PubMed ID: 1591557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.
    Circulation; 2000 Jun; 101(24):2788-94. PubMed ID: 10859283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.